Novo Nordisk Sues Eli Lilly Over Misleading Weight-Loss Drug Ads

Novo Nordisk has filed a lawsuit against rival Eli Lilly in a U.S. federal court, alleging false advertising in the booming weight-loss drug market.

Details of the Lawsuit

Novo alleges that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines.

The lawsuit was filed in the U.S. District Court in New Jersey, accusing Lilly of violating federal and state false advertising and unfair competition laws, including the Lanham Act.

Company Positions

Lilly has not yet commented on the lawsuit. The case highlights the intense competition between the two companies in the obesity drug market, which analysts expect to be worth more than $100 billion by 2030.

Context

Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but later lost the lead to Eli Lilly after Zepbound launched in the U.S. Last year, Novo replaced its CEO and issued multiple profit warnings as it fell further behind Lilly. However, this year Novo launched its oral Wegovy pill ahead of Lilly, which launched its own pill in April.

Potential Financial Impact

Both companies are set to report quarterly results in the coming weeks. The lawsuit could affect Lilly's reputation and lead to changes in its advertising campaigns, but the direct financial impact remains unclear.